ATH 25.0% 0.5¢ alterity therapeutics limited

Stamler, most likely, has no access to the patient data produced...

  1. 2,781 Posts.
    lightbulb Created with Sketch. 966
    Stamler, most likely, has no access to the patient data produced and collected in 23 different study locations. In fact, nobody has. Data collection will happen, IMO, at the end of the study, and only at the end of the study the key of the treatment group will be opened. But in the open study, we can see the effect of a big dose of ATH434 on clinical scores, the iron content of the brain, Nfl, and alpha-synuclein. I feel, that this info is much more informative than some "leaks" or rumors about the randomized study.
    Some problems were getting enough cases for the open study. So the numbers for 6 months MRI examination can be still a bit small but, sure, they have enough to see the trend in all the important measures. Let us see if we need to wait until June.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.22M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $10.54K 2.185M

Buyers (Bids)

No. Vol. Price($)
59 83226460 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 20397608 18
View Market Depth
Last trade - 10.13am 07/06/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.